Literature DB >> 7076853

An abnormal triglyceride-rich lipoprotein containing excess sialylated apolipoprotein C-III.

G Holdsworth, J Stocks, P Dodson, D J Galton.   

Abstract

An abnormal triglyceride-rich lipoprotein has been isolated from some patients with chronic renal failure or severe hypertriglyceridemia. The abnormal lipoprotein was characterized by an increased content of apolipoprotein (apo) C-III-2 (57.5% of total apo C-III peptides compared with 35.5% for controls, P less than 0.001) as characterized by isoelectric focusing and scanning densitometry. As determined by a substrate competition assay, the abnormal lipoprotein was a less efficient substrate for purified bovine milk lipoprotein lipase than control lipoproteins. Neuraminidase digestion of abnormal or control lipoprotein resulted in a reduction of the apo C-III-2 band with a corresponding increase in the region of apo C-III-0, which suggests that the increased content of apo C-III-2 in the abnormal is due to excessive sialylation of the C-III peptide. Limited incubation of the abnormal lipoproteins with neuraminidase caused a partial loss of sialic acid and resulted in a triglyceride-rich lipoprotein with a normal C-III-2:C-III-1 ratio. This preparation displayed normal substrate interaction with lipoprotein lipase. Three severely hypertriglyceridemic patients with the abnormal lipoprotein showed a marked reduction in serum triglyceride concentration, which is associated with a reversion to a normal C-peptide profile after dietary therapy. The results suggest that the extent of sialylation of the apo C-III peptide carried on triglyceride-rich lipoproteins may be critical for their interaction with lipoprotein lipase.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7076853      PMCID: PMC370147          DOI: 10.1172/jci110532

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  21 in total

1.  The use of density gradient centrifugation for the separation of serum lipoproteins.

Authors:  R H Hinton; Y Al-Tamer; A Mallinson; V Marks
Journal:  Clin Chim Acta       Date:  1974-06-28       Impact factor: 3.786

2.  A rapid electrophoretic technique for identification of subunit species of apoproteins in serum lipoproteins.

Authors:  J P Kane
Journal:  Anal Biochem       Date:  1973-06       Impact factor: 3.365

3.  Heterogeneity of human plasma very low density lipoproteins. Separation of species differing in protein components.

Authors:  V G Shore; B Shore
Journal:  Biochemistry       Date:  1973-01-30       Impact factor: 3.162

4.  Inhibition of lipoprotein lipase by an apoprotein of human very low density lipoprotein.

Authors:  W V Brown; M L Baginsky
Journal:  Biochem Biophys Res Commun       Date:  1972-01-31       Impact factor: 3.575

5.  Solubility in aqueous solutions of ethanol of the small molecular weight peptides of the serum very low density and high density lipoproteins: relevance to the recovery problem during delipidation of serum lipoproteins.

Authors:  A M Scanu; C Edelstein
Journal:  Anal Biochem       Date:  1971-12       Impact factor: 3.365

6.  The fluorometric assay of triglyceride by a semiautomated method.

Authors:  D G Cramp; G Robertson
Journal:  Anal Biochem       Date:  1968-10-24       Impact factor: 3.365

7.  Changing relative proportions of apolipoproteins CII and CIII of very low density lipoproteins in hypertriglyceridaemia.

Authors:  L A Carlson; D Ballantyne
Journal:  Atherosclerosis       Date:  1976 May-Jun       Impact factor: 5.162

8.  Serum lipoproteins and apolipoproteins in rats with streptozotocin-induced diabetes.

Authors:  H Bar-On; P S Roheim; H A Eder
Journal:  J Clin Invest       Date:  1976-03       Impact factor: 14.808

9.  Tissue lipoprotein lipase in normal individuals and in individuals with exogenous hypertriglyceridemia and the relationship of this enzyme to assimilation of fat.

Authors:  W R Harlan; P S Winesett; A J Wasserman
Journal:  J Clin Invest       Date:  1967-02       Impact factor: 14.808

10.  Simple liquid-liquid partition system for isolation of labeled oleic acid from mixtures with glycerides.

Authors:  P Belfrage; M Vaughan
Journal:  J Lipid Res       Date:  1969-05       Impact factor: 5.922

View more
  14 in total

1.  Impaired postprandial lipemic response in chronic kidney disease.

Authors:  Jeffrey M Saland; Lisa M Satlin; Jeanna Zalsos-Johnson; Serge Cremers; Henry N Ginsberg
Journal:  Kidney Int       Date:  2016-05-07       Impact factor: 10.612

2.  Complexities of plasma apolipoprotein C-III metabolism.

Authors:  Frank M Sacks; Chunyu Zheng; Jeffrey S Cohn
Journal:  J Lipid Res       Date:  2011-03-18       Impact factor: 5.922

3.  Deoxyribonucleic acid polymorphism in the apolipoprotein A-1-C-III gene cluster. Association with hypertriglyceridemia.

Authors:  A Rees; J Stocks; C R Sharpe; M A Vella; C C Shoulders; J Katz; N I Jowett; F E Baralle; D J Galton
Journal:  J Clin Invest       Date:  1985-09       Impact factor: 14.808

4.  Haplotypes identified by DNA polymorphisms at the apolipoprotein A-1 and C-III loci and hypertriglyceridaemia. A study in a Japanese population.

Authors:  A Rees; J Stocks; H Paul; Y Ohuchi; D Galton
Journal:  Hum Genet       Date:  1986-02       Impact factor: 4.132

5.  Plasma apolipoprotein C-III metabolism in patients with chronic kidney disease.

Authors:  Esther M M Ooi; Doris T Chan; Gerald F Watts; Dick C Chan; Theodore W K Ng; Gursharan K Dogra; Ashley B Irish; P Hugh R Barrett
Journal:  J Lipid Res       Date:  2011-02-06       Impact factor: 5.922

6.  Demonstration of an abnormality of C apoprotein of very low density lipoprotein in patients with gout.

Authors:  D G Macfarlane; C A Midwinter; P A Dieppe; C H Bolton; M Hartog
Journal:  Ann Rheum Dis       Date:  1985-06       Impact factor: 19.103

7.  Relationship of an abnormal plasma lipoprotein to protection from atherosclerosis in the cholesterol-fed diabetic rabbit.

Authors:  P Brecher; A V Chobanian; D M Small; W Van Sickle; A Tercyak; A Lazzari; J Baler
Journal:  J Clin Invest       Date:  1983-11       Impact factor: 14.808

8.  Disialylated apolipoprotein C-III proteoform is associated with improved lipids in prediabetes and type 2 diabetes.

Authors:  Juraj Koska; Hussein Yassine; Olgica Trenchevska; Shripad Sinari; Dawn C Schwenke; Frances T Yen; Dean Billheimer; Randall W Nelson; Dobrin Nedelkov; Peter D Reaven
Journal:  J Lipid Res       Date:  2016-03-03       Impact factor: 5.922

9.  Chronic kidney disease delays VLDL-apoB-100 particle catabolism: potential role of apolipoprotein C-III.

Authors:  Doris T Chan; Gursharan K Dogra; Ashley B Irish; Esther M Ooi; P Hugh Barrett; Dick C Chan; Gerald F Watts
Journal:  J Lipid Res       Date:  2009-06-21       Impact factor: 5.922

10.  ApoCIII-enriched LDL in type 2 diabetes displays altered lipid composition, increased susceptibility for sphingomyelinase, and increased binding to biglycan.

Authors:  Anne Hiukka; Marcus Ståhlman; Camilla Pettersson; Malin Levin; Martin Adiels; Susanne Teneberg; Eeva S Leinonen; Lillemor Mattsson Hultén; Olov Wiklund; Matej Oresic; Sven-Olof Olofsson; Marja-Riitta Taskinen; Kim Ekroos; Jan Borén
Journal:  Diabetes       Date:  2009-06-05       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.